<DOC>
	<DOC>NCT01127269</DOC>
	<brief_summary>Primary Objective: Percentage of patients achieving Glycosylated Hemoglobin (HbA1c) &lt; 7% with no severe or nocturnal hypoglycemic episodes at 6 months Secondary Objectives: - Glycosylated Hemoglobin (HbA1c) change from baseline to 6 months - Insulin glargine dose at 3 and 6 months - Hypoglycemic episodes (all types)</brief_summary>
	<brief_title>Safety and Effectiveness Study of Insulin Glargine (LANTUS) Initiation and Titration in Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Inclusion criteria: Patients with a diagnosis of type 2 diabetes for more than 6 months Patients treated with Oral AntiDiabetics (OADs monotherapy or combination) with an HbA1c &gt;7% and &lt;10% and/or treated with NPH insulin with HbA1c &gt;7% and &lt;10% or treated with NPH insulin who have experienced severe and/or nocturnal hypoglycemia in the last 6 months. Ability to perform SMBS and insulin selftitration under the physicians guidance. Body Mass Index (BMI) &gt;21 kg/ m2. Signature of informed consent. Exclusion criteria: Hospitalized patients. Pregnant women or with the intention of becoming pregnant. Unexplained weight loss of more than 10% in the last 6 months. Women with child bearing potential not using effective contraceptive methods. Women in breast feeding period. Patients on chronic treatment with systemic corticosteroids or protease inhibitors. History of drug or alcohol abuse. Diabetic retinopathy with surgical treatment in 3 months previous to study entry or patients that could require surgical treatment in the following 6 months to study entry. Major systemic disease clinically important that would interfere with implementation or interpretation of the study, at the discretion of the investigator. Renal failure known as creatinine &gt; 1.4 mg/dl in women and &gt; 1.5 mg/dl in men. Known hypersensitivity to glargine or any of its excipients. Patients with history of hospitalization due to cardiovascular event, cardiovascular procedure in the past 6 months. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>